13.34

1.70% -0.28

Day One Biopharmaceuticals Inc (DAWN)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$13.62

Offen:

$13.55

24-Stunden-Volumen:

132.98K

Relative Volume:

0.13

Marktkapitalisierung:

$1.37B

Einnahmen:

Nettoeinkommen (Verlust:

$-167.48M

KGV:

-5.80

EPS:

-2.3

Netto-Cashflow:

$-197.47M

1W Leistung:

-6.51%

1M Leistung:

-10.33%

6M Leistung:

-9.48%

1J Leistung:

+12.31%

1-Tages-Spanne:

$13.35

$13.63

1-Wochen-Bereich:

$12.86

$14.35

52-Wochen-Spanne:

$11.30

$18.07

Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile

Firmenname

Day One Biopharmaceuticals Inc

Sektor

Healthcare (1195)

Branche

Biotechnology (683)

Telefon

650 484-0899

Adresse

2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE

Mitarbeiter

174

Twitter

Nächster Verdiensttermin

Neueste SEC-Einreichungen

DAWN's Discussions on Twitter

Vergleichen Sie DAWN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
DAWN	13.37	1.37B	0	-167.48M	-197.47M	-2.30
VRTX	447.00	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	741.05	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	587.23	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.40	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.75	24.49B	3.30B	-501.07M	1.03B	11.54

Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-10-09	Bestätigt	Needham	Buy
2024-08-01	Hochstufung	BofA Securities	Underperform → Buy
2024-04-24	Bestätigt	Needham	Buy
2023-04-25	Herabstufung	BofA Securities	Buy → Underperform
2023-02-08	Eingeleitet	CapitalOne	Overweight
2023-02-03	Eingeleitet	Oppenheimer	Perform
2022-12-15	Eingeleitet	H.C. Wainwright	Buy
2022-12-14	Eingeleitet	Needham	Buy
2022-12-05	Eingeleitet	Goldman	Buy
2022-12-01	Eingeleitet	BofA Securities	Buy

Alle ansehen

Day One Biopharmaceuticals Inc Aktie (DAWN) Neueste Nachrichten

Nov 20, 2024

Day One Biopharmaceuticals announces R&D leadership change - Investing.com India

Nov 20, 2024

Day One Biopharmaceuticals announces R&D leadership change By Investing.com - Investing.com UK

Nov 20, 2024

Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development - GlobeNewswire

Nov 20, 2024

Day One Biopharmaceuticals, Inc. Announces the Retirement of Samuel Blackman as Co-Founder and Head of Research & Development, Effective at the End of 2024 - Marketscreener.com

Nov 20, 2024

Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High? - MSN

Nov 20, 2024

Nov 19, 2024

Day one Biopharmaceuticals COO sells shares worth $34,372 By Investing.com - Investing.com South Africa

Nov 19, 2024

Day One Biopharmaceuticals CEO sells $139,420 in stock - Investing.com

Nov 19, 2024

Day one Biopharmaceuticals COO sells shares worth $34,372 - Investing.com

Nov 19, 2024

Day One Biopharmaceuticals CEO sells $139,420 in stock By Investing.com - Investing.com UK

Nov 19, 2024

First Turn Management LLC Invests $13.20 Million in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat

Nov 19, 2024

Nov 18, 2024

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Sees Large Increase in Short Interest - MarketBeat

Nov 18, 2024

First Week of July 2025 Options Trading For Day One Biopharmaceuticals (DAWN) - Nasdaq

Nov 18, 2024

Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times

Nov 18, 2024

Day One Biopharmaceuticals to Present at Piper Sandler Healthcare Conference | DAWN Stock News - StockTitan

Nov 18, 2024

Nov 17, 2024

59,259 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Bought by GSA Capital Partners LLP - MarketBeat

Nov 17, 2024

Nov 11, 2024

(DAWN) Trading Advice - Stock Traders Daily

Nov 11, 2024

TimesSquare Capital Management LLC Has $25.46 Million Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat

Nov 11, 2024

Nov 09, 2024

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells $180,257.35 in Stock - MarketBeat

Nov 09, 2024

Nov 07, 2024

Day one biopharmaceuticals head of R&D sells $8,010 in stock By Investing.com - Investing.com Canada

Nov 04, 2024

Day one biopharmaceuticals head of R&D sells $8,010 in stock - Investing.com

Nov 04, 2024

Forecast: Analysts Think Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Business Prospects Have Improved Drastically - Simply Wall St

Nov 04, 2024

Bullish: Analysts Just Made A Huge Upgrade To Their Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Forecasts - Yahoo Finance

Nov 04, 2024

Equities Analysts Issue Forecasts for DAWN Q1 Earnings - MarketBeat

Nov 04, 2024

Nov 03, 2024

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Nov 03, 2024

Nov 01, 2024

We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth - Yahoo Finance

Nov 01, 2024

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 01, 2024

Day One Biopharmaceuticals’ Revenue at Risk: Heavy Dependence on Few Key Customers - TipRanks

Nov 01, 2024

Oct 31, 2024

(DAWN) Proactive Strategies - Stock Traders Daily

Oct 31, 2024

Day One Biopharmaceuticals (NASDAQ:DAWN) Issues Earnings Results, Beats Estimates By $0.58 EPS - MarketBeat

Oct 31, 2024

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up After Earnings Beat - MarketBeat

Oct 31, 2024

Pre-Market Trading Boosts Day One (DAWN) Amid High OJEMDA Demand - Stocks Telegraph

Oct 31, 2024

Day One Biopharmaceuticals (NASDAQ:DAWN) Given "Buy" Rating at HC Wainwright - MarketBeat

Oct 31, 2024

ChromaDex Q3 2024 Earnings Preview - MSN

Oct 31, 2024